Passage Bio, INC. (PASG) — SEC Filings

Overview

Passage Bio, INC. (PASG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: Passage BIO, Inc. filed an 8-K on April 20, 2026, to disclose information under Regulation FD. The filing includes exhibits such as financial statements and other documents, but no specific financial figures or material events were detailed in the provided text.

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Passage Bio, INC. is neutral.

Filing Type Overview

Passage Bio, INC. (PASG) has filed 18 8-K, 1 ARS, 1 DEFA14A, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 3 SC 13D/A, 2 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• Passage BIO, Inc. Files 8-K — 8-K · Apr 20, 2026 Risk: low
  Passage BIO, Inc. filed an 8-K on April 20, 2026, to disclose information under Regulation FD. The filing includes exhibits such as financial statements and oth
• Passage BIO Files Annual Report — ARS · Apr 7, 2026 Risk: low
  Passage BIO, Inc. filed its Annual Report to Security Holders (ARS) on April 7, 2026, for the period ending December 31, 2025. The report details the company's
• DEFA14A Filing — DEFA14A · Apr 7, 2026
• Passage Bio Narrows Q3 Loss Amid R&D Cuts, Cash Position Improves — 10-Q · Nov 10, 2025 Risk: high
  Passage Bio, Inc. reported a net loss of $7.7 million for the three months ended September 30, 2025, a significant improvement from the $19.3 million net loss i
• Passage BIO Announces Board and Executive Changes — 8-K · Sep 18, 2025 Risk: medium
  Passage BIO, Inc. announced on September 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported
• Passage Bio Narrows Losses, Boosts Cash Amid R&D Cuts — 10-Q · Aug 12, 2025 Risk: high
  Passage BIO, Inc. reported a net loss of $9.385 million for the three months ended June 30, 2025, a significant improvement from the $15.991 million net loss in
• Passage BIO, Inc. Files 8-K Report — 8-K · Jul 29, 2025 Risk: medium
  On July 28, 2025, Passage BIO, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself, but it
• Passage BIO, Inc. Files 8-K with Corporate Updates — 8-K · Jul 14, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on July 14, 2025, reporting events as of July 10, 2025. The filing indicates material modifications to security holder rights, am
• Passage BIO Files 8-K — 8-K · Jun 23, 2025 Risk: low
  Passage BIO, Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The filing does not contain specific details about new materia
• Passage BIO, Inc. Reports on Security Holder Vote — 8-K · May 30, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on May 30, 2025, reporting on a matter submitted to a vote of its security holders on May 28, 2025. The filing does not disclose
• Passage BIO, Inc. Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Passage BIO, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the biological products sector. Its pr
• Passage BIO Files 2025 Proxy Statement — DEF 14A · Apr 16, 2025 Risk: low
  Passage BIO, Inc. filed its definitive proxy statement on April 16, 2025, for its annual meeting of stockholders on May 28, 2025. The filing outlines the compan
• Passage BIO Files 2024 10-K — 10-K · Mar 4, 2025 Risk: medium
  Passage BIO, Inc. filed its 2024 10-K on March 4, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focused o
• Passage BIO Faces Delisting Concerns — 8-K · Jan 31, 2025 Risk: high
  Passage BIO, Inc. filed an 8-K on January 31, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer o
• Passage BIO, Inc. Files 8-K on Operations and Disposals — 8-K · Jan 10, 2025 Risk: medium
  Passage BIO, Inc. filed an 8-K on January 10, 2025, reporting events as of January 8, 2025. The filing pertains to results of operations, cost associated with e
• SC 13G Filing — SC 13G · Nov 14, 2024
• Passage BIO, Inc. Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: low
  Passage BIO, Inc. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the biological products sector. Ke
• Passage BIO Files 8-K — 8-K · Oct 24, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on October 24, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
• Passage BIO, Inc. Files 8-K Report — 8-K · Sep 16, 2024 Risk: low
  On September 16, 2024, Passage BIO, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, including financial stat
• Passage BIO Appoints New CMO and Board Member — 8-K · Sep 10, 2024 Risk: medium
  Passage BIO, Inc. announced on September 9, 2024, changes in its executive team and board of directors. Specifically, Dr. Michael J. Boyle has been appointed as
• Passage BIO Reports Material Impairment — 8-K · Sep 6, 2024 Risk: medium
  Passage BIO, Inc. reported a material impairment on September 4, 2024, related to its gene therapy programs. The company recognized a significant impairment cha
• Versant Venture Capital VI Amends Passage BIO Stake — SC 13D/A · Aug 9, 2024 Risk: medium
  Versant Venture Capital VI, L.P. filed an amendment (No. 3) to its Schedule 13D on August 9, 2024, regarding its holdings in Passage BIO, Inc. The filing indica
• SC 13G/A Filing — SC 13G/A · Aug 9, 2024
• Passage BIO Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Passage BIO, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial figures and
• Passage BIO Faces Delisting Notice — 8-K · Aug 2, 2024 Risk: high
  Passage BIO, Inc. filed an 8-K on August 1, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in
• Passage BIO, Inc. Files 8-K: Material Agreement, Financials, Officer Changes — 8-K · Aug 1, 2024 Risk: medium
  Passage BIO, Inc. announced on July 26, 2024, that it entered into a material definitive agreement. The company also reported its results of operations and fina
• Passage BIO Files 8-K — 8-K · Jul 16, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on July 16, 2024, to report on other events and financial statements. The filing does not contain specific details about new mate
• Versant Venture Capital VI Amends Passage BIO Stake — SC 13D/A · May 29, 2024 Risk: medium
  Versant Venture Capital VI, L.P. filed an amendment (No. 2) to its Schedule 13D on May 29, 2024, regarding its holdings in Passage BIO, Inc. The filing indicate
• Passage BIO Reports on Shareholder Vote Matters — 8-K · May 22, 2024 Risk: low
  Passage BIO, Inc. filed an 8-K on May 21, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain details about spec
• Passage BIO, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  Passage BIO, Inc. (PASG) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Passage BIO, Inc. filed a 10-Q report for the period ending March 31, 202
• OrbiMed Amends Passage BIO Stake Filing — SC 13D/A · Apr 12, 2024 Risk: medium
  OrbiMed Advisors LLC, along with affiliated entities, has amended its Schedule 13D filing for Passage BIO, Inc. as of April 12, 2024. The filing indicates a cha
• Passage Bio Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 9, 2024 Risk:
  Passage BIO, Inc. (PASG) filed a Proxy Statement (DEF 14A) with the SEC on April 9, 2024. Passage Bio, Inc. will hold its 2024 Annual Meeting of Stockholders on
• SC 13G Filing — SC 13G · Mar 29, 2024
• Passage BIO, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 4, 2024 Risk: medium
  Passage BIO, Inc. (PASG) filed a Annual Report (10-K) with the SEC on March 4, 2024. Passage BIO, Inc. filed its 10-K report for the fiscal year ending December
• New Mountain Capital to Acquire Passage BIO for $1.4B — 8-K · Feb 29, 2024 Risk: medium
  Passage BIO, Inc. announced on February 29, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of private equity firm New Moun
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Passage BIO Confirms Nasdaq Listing for Common Stock — 8-K · Jan 5, 2024
  Passage BIO, Inc. filed an 8-K on January 5, 2024, to disclose that its Common Stock, with a $0.0001 Par Value Per Share, is registered on The Nasdaq Stock Mark

Related Companies

BIO · Passage BIO, Inc. · PBIO · PASO

Frequently Asked Questions